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Aims/hypothesis The incidence of type 1 diabetes is increasing at a rate of 3-5% per 
year. Genetics cannot fully account for this trend, suggesting an influence of 
environmental factors. The accelerator hypothesis proposes an effect of metabolic 
factors on type 1 diabetes risk. To test this in the TrialNet Pathway to Prevention (PTP) 
cohort, we analysed the influence of BMI, weight status and insulin resistance on 
progression from single to multiple islet autoantibodies (Aab) and progression from 
normoglycaemia to diabetes. 
Methods HOMA1-IR was used to estimate insulin resistance in Aab-positive PTP 
participants. Cox proportional hazards models were used to evaluate the effects of BMI, 
BMI percentile (BMI%), weight status and HOMA1-IR on the progression of 
autoimmunity or the development of diabetes. 
Results Data from 1,310 single and 1,897 multiple Aab-positive PTP participants were 
included. We found no significant relationships between BMI, BMI%, weight status or 
HOMA1-IR and the progression from one to multiple Aabs. Similarly, among all Aab-
positive participants, no significant relationships were found between BMI, weight status 
or HOMA1-IR and progression to diabetes. Diabetes risk was modestly increased with 
increasing BMI% among the entire cohort, in obese participants 13-20 years of age, and 




Conclusions/interpretation Analysis of the accelerator hypothesis in the TrialNet PTP 
cohort does not suggest a broad influence of metabolic variables on diabetes risk. 
Efforts to identify other potentially modifiable environmental factors should continue. 
 
Keywords: Accelerator hypothesis, BMI, Diabetes in childhood, HOMA1-IR, Insulin 
sensitivity and resistance, Pancreatic autoantibodies, Pathway to Prevention, Prediction 




Aab  Autoantibodies 
BMI%  BMI percentile 
CDC  Centers for Disease Control and Prevention 
DPT-1  Diabetes Prevention Trial of Type 1 Diabetes 
GAD65 Glutamic acid decarboxylase 65 
IA-2/ICA512 Islet-antigen 2 
IQR  Interquartile range 
PTP  Pathway to Prevention 




Type 1 diabetes is a heterogeneous disorder in which a primary or secondary 
islet insult renders the beta cell antigenic, leading to T-lymphocyte infiltration and 
production of pro-inflammatory cytokines such as IL-1β, TNFα and IFNγ. Over the past 
30 years, there has been a global and largely unexplained increase in the incidence of 
type 1 diabetes, especially among younger populations [1, 2]. Between 1989-2003, the 




among children aged 0-4 years, 5-9 years and 10-14 years, respectively [3], while the 
SEARCH for Diabetes in Youth Study demonstrated a similar increase of 2.6% among 
American children from 2002-2009 [4]. High-risk HLA Class II alleles including HLA-DR3 
and 4 and DQ2 and 8 increase the risk of type 1 diabetes [5], but the prevalence of 
these high-risk HLA alleles has remained largely stable [6]. Thus, inheritance alone is 
not likely to account for the rising prevalence of type 1 diabetes, suggesting roles for 
nongenetic and/or environmental factors. 
Environmental influence has been well illustrated by twin studies [7] and reports 
showing that first-generation children of immigrant parents from regions with a low 
prevalence of type 1 diabetes experience a risk most similar to that in their new country 
[8]. Commonly implicated environmental factors include decreased rates of infection 
due to antibiotics and vaccination (the hygiene hypothesis) [9], viral infections [10], 
dietary factors and changes in the gut microbiome [11], decreased intake and 
endogenous synthesis of vitamin D [12], seasonality [13] and exposure to endocrine 
disrupting chemicals [14]. 
The accelerator or overload hypothesis is another highly favoured explanation 
and postulates that chronically increased beta cell secretory demand, occurring as a 
result of overnutrition, obesity and insulin resistance, may lead to activation of intrinsic 
beta cell stress pathways that either trigger autoimmunity through formation of 
neoantigens or act independently to accelerate autoimmune-mediated beta cell death 




in early life is suggested to be a risk factor both for the development of diabetes as well 
as for disease presentation at a younger age [16-19]. Moreover, rates of obesity have 
increased in children. For example, obesity amongst US children more than doubled in 
some age groups from 1976-1980 to 2009-2010 [20]. 
Data from the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1), which 
served as the precursor to the Type 1 Diabetes TrialNet study, revealed a modest 
impact of metabolic variables on diabetes risk [21, 22]. However, a DPT-1 Risk Score, 
which includes BMI, has proven to be predictive of progression to diabetes [23-25]. In 
another analysis, data from over 9,000 German and Austrian children between the 
years 1990-2003 revealed higher BMI and weight in those diagnosed with diabetes than 
those in the control reference population [17]. 
Given this background, the goal of this study was to test the accelerator 
hypothesis within a contemporary international and mixed-age cohort at increased 
genetic risk of diabetes. Type 1 Diabetes TrialNet is an ongoing clinical trial with centres 
located in the USA, Canada, the UK, Germany, Italy, Australia and New Zealand. In the 
TrialNet Pathway to Prevention (PTP) cohort, blood relatives of individuals with type 1 
diabetes are screened for the presence of pancreatic islet autoantibodies (Aabs). Those 
positive for at least one Aab are then followed up longitudinally for the development of 
additional islet Aabs, dysglycaemia and diabetes. By use of data derived from the 
TrialNet PTP cohort, we tested whether BMI, obesity or overweight status and/or insulin 




measured by the conversion from single to multiple Aab status) or ultimately to the 
progression to type 1 diabetes. 
 
Methods 
Participants and follow-up Details of the enrolment criteria for entry into the 
TrialNet PTP cohort, which began in 2001, have been described previously [26]. In brief, 
nondiabetic first-degree relatives (ages 1-45 years) and second or third-degree relatives 
(ages 1-20 years) of individuals with type 1 diabetes were screened for the presence of 
pancreatic islet Aabs in a stepwise fashion. Participants were tested first for the 
presence of GAD65 (glutamic acid decarboxylase 65), insulin, or IA-2/ICA512 (islet-
antigen 2) Aabs, followed by measurement of islet cell Aabs (ICA) or zinc transporter 8 
(ZnT8) Aabs if any one initial test was positive [27]. Measurement of ZnT8 was initiated 
in 2004 [28], and was consistently measured in the PTP cohort starting in 2012. 
Confirmed Aab positive (Aab+) individuals were invited to participate in longitudinal 
observation with either semi-annual or annual monitoring. The strategy for monitoring 
included measurement of height and weight, and performance of a standard protocol 
OGTT [29]. 
A total of 134,937 eligible individuals were screened from 2001 through June 30, 
2014 (electronic supplementary material [ESM] Fig. 1). A total of 2,299 individuals were 
confirmed on repeat testing to be single Aab+ (GAD65, insulin or IA-2/ICA512), while a 




focus on those who had at least one monitoring visit (1,310 single Aab+ and 1,897 
multiple Aab+ individuals). Participants who later entered prevention trials were 
censored at the time of initial enrolment into the prevention trial. All participants 
provided written informed consent prior to commencement of data collection. The study 
was approved by the ethical boards of all participating institutions and was conducted 
according to standards established by the Declaration of Helsinki. 
 
Laboratory analyses Aab status was assessed using procedures outlined by 
the Diabetes Antibody Standardization Program and described in detail in previous 
publications [30]. Glucose was measured using the glucose oxidase method [31]. 
Insulin was initially measured by radioimmunoassay [32]; however, this was transitioned 
to a TOSOH AIA (Automated Immunoassay) (San Francisco, CA, USA) in 2009-2010. 
HOMA1-IR was calculated as described previously using values obtained from the first 
OGTT performed during the initial monitoring visit [21]. BMI was calculated for each 
participant using data from the first monitoring visit. For children and adolescents ≤19 
years of age, BMI z scores (SDs) were calculated using the Centers for Disease Control 
and Prevention (CDC) SAS program for the 2000 CDC growth charts 
(www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm); z scores were then 
used to calculate BMI percentile values using the lambda-mu-sigma (LMS) method as 
previously described [33]. BMI percentile values for age 20 years were applied to all 




participants and 201 (10.6%) of participants with multiple Aabs. BMI, BMI percentile 
(BMI%) and HOMA1-IR were defined as continuous variables, whereas BMI/BMI% 
values were also analysed as categorical variables. BMI category divisions included 
underweight (BMI <18.5 kg/m2 and/or BMI% <5%), normal (BMI ≥ 18.5 kg/m2 and < 25 
kg/m2 and/or BMI percentile ≥ 5% and < 85%), overweight (BMI ≥ 25 kg/m2 and < 30 
kg/m2 and/or BMI percentile ≥ 85% and < 95%) and obese (BMI ≥ 30 kg/m2 and/or BMI 
percentile ≥95%). Diabetes was diagnosed according to American Diabetes Association 
criteria (confirmed fasting plasma glucose ≥ 7.0 mmol/L, random glucose ≥ 11.1 
mmol/L, or HbA1c > 6.5% [48 mmol/mol]) [34]. 
 
Statistical methods Categorical variables were compared among groups by Pearson’s 
χ2 tests or Fisher Exact tests when cell sizes were insufficient. Continuous variables 
were summarised either by mean ± SD or median and interquartile range (IQR). Two-
sample t tests were used to compare the difference of means for these variables 
between groups. The association of HOMA1-IR, BMI, BMI percentile and time to 
progression from single to multiple Aab conversion or time to progression to a clinical 
diagnosis of type 1 diabetes was adjusted for potential confounders using the 
multivariate Cox proportional hazards model. Assumptions for proportionality of hazards 
were tested for in these models [35], and age at the initial screen, sex, HLA risk, 
relationship to proband, and race were adjusted for in the model. Age groups were 




metabolic variables and age groups were also assessed using first-order interaction 
terms in the Cox models as well as in stratified analyses based on age groups. All tests 
of significance were two-sided, where p values < 0.05 were considered to be statistically 
significant. Statistical analyses were performed with SAS Version 9.2 (Cary, NC, USA). 
 
Results 
Anthropometric measurements and metabolic data were collected on PTP 
participants confirmed to have a single Aab (n=1,310) and those with multiple Aabs 
(n=1,897) and compared between groups. Participants in both the single and multiple 
Aab+ groups were predominantly white (82.6% and 86.7%, respectively), non-Hispanic 
(80.1% and 85.5%, respectively) and first-degree relatives of probands. There was a 
significantly higher percentage of females in the single Aab+ cohort (60.8%) vs the 
multiple Aab+ cohort (49.5%). HLA DR3 or DR4 was present in 66.9% of single Aab+ 
and 71.9% of multiple Aab+ individuals (Table 1). 
Individuals confirmed as single Aab+ were older at initial screening than multiple 
Aab+ participants (p<0.001). Of the single Aab+ group, 5.2% (n=69) of participants were 
underweight, 46.6% (n=611) were categorised as normal weight, 21.2% (n=278) were 
overweight and 19.1% (n=250) were obese. Of the multiple Aab+ group, 6.9% (n=131) 
were underweight, 53.8% (n=1020) were normal weight, 14.9% (n=282) were 
overweight and 13.9% (n=263) were obese. Single Aab+ individuals also had higher 




BMI/BMI percentiles were next analysed as continuous variables and participants 
were also stratified by weight category as outlined in the Methods. Characteristics of 
obese and nonobese (underweight, normal weight and overweight) PTP participants are 
shown in Table 2. Consistent with relationships shown in Table 1, a higher percentage 
of obese individuals were single Aab+ compared with nonobese individuals (48.7% vs 
40.1%, respectively; p=0.0004). Obese participants tended to be older at initial 
screening than nonobese participants (median age: 28.2 vs 11.9 years, respectively; 
p<0.001). However, overall age ranges were overlapping for obese and nonobese 
participants: 1.30–45.99 years vs 1.01–46.59 years, respectively (ESM Table 1). 
Among the 1,310 confirmed single Aab+ PTP participants who had at least one 
monitoring visit, 288 (22.0%) individuals progressed to multiple Aab+ status during 
follow-up. The median follow-up time of single Aab+ individuals was 2.5 years (IQR 
1.32-4.38 years). Univariate analysis confirmed an increased risk of progression to 
multiple positive Aabs or diabetes in younger, male individuals [36]. Interestingly, 
univariate analysis also suggested a protective effect of overweight status on the risk of 
progression to multiple Aabs (HR 0.64, 95% CI 0.46, 0.88; p=0.01). Similarly, higher 
BMI and BMI percentiles were also associated with a moderately decreased risk of 
progression to multiple Aabs (p<0.01). No other significant associations were seen 





Cox proportional hazards models were used next to evaluate the influence of 
HOMA1-IR, BMI, BMI percentile and BMI category on the progression from single to 
multiple Aabs after adjusting for age, sex, HLA risk, relationship to proband and race 
(Table 4). In the adjusted analysis, the protective effect of BMI or overweight status did 
not persist, and no statistically significant relationships were revealed between BMI 
(p=0.73), BMI percentile (p=0.27), overweight (p=0.34) or obese (p=0.96) status, or 
HOMA1-IR (p=0.47) and risk of progression from single to multiple Aab status. Similarly, 
no relationship was seen between underweight status and this endpoint (p=0.70). 
Among 3,207 single or multiple Aab+ PTP participants, 647 (20.2%) individuals 
progressed to diabetes. Type 1 diabetes developed in 579/1,897 (30.5%) individuals 
with multiple Aabs and only 68/1,310 (5.2%) individuals with a confirmed single Aab 
over the median follow-up time of 2.31 years (IQR 0.97-4.20 years). Individuals positive 
for HLA DR3 and DR4 demonstrated the expected increase in risk of progression to 
diabetes (Table 3). Univariate analysis suggested an increased risk of underweight 
status (HR 1.90, 95% CI 1.46, 2.47), but again a protective effect of obese status on the 
risk of progression to diabetes as an outcome (HR 0.77, 95% CI 0.60, 0.98; p=0.032). 
Higher BMI was also found to be associated with a decreased risk of progression to 
diabetes in univariate analysis (HR 0.93, 95% CI 0.92,0.95; p<0.001). However, after 
adjusting for age, sex, race, relationship to proband and HLA risk, no significant 
associations between BMI (p=0.29), underweight (p=0.96), overweight (p=0.08) or 




multiple Aab+ participants were revealed (Table 4). This analysis revealed a modestly 
increased risk of diabetes with increasing BMI% (HR 1.004, 1.00-1.01; p=0.04). 
Furthermore, there was a significant interaction between obesity and age group in 
relation to time to type 1 diabetes (p=0.04); i.e. there was a differential impact of obesity 
on time to type 1 diabetes between age groups. Specifically, obesity significantly 
increased the risk of type 1 diabetes in individuals who were 13-20 years old (HR=2.06, 
p=0.045; Table 5). 
We next stratified participants by Aab status, and Cox proportional hazards 
models were used to analyse progression to type 1 diabetes as an outcome. Again, we 
found no associations between BMI, BMI percentile, obesity or overweight status, or 
HOMA1-IR and time to progression to diabetes when single Aab+ individuals and 
multiple Aab+ individuals were analysed separately (Table 5). 
Finally, Aab+ individuals were stratified by age, such that age at initial screening 
was categorised into three groups: <13 vs 13 to 20 vs over 20 years of age. Subgroup 
analysis revealed that obese participants aged 13-20 years displayed a significantly 
increased risk of progression to diabetes compared with age-matched normal-weight 
participants (HR 2.06, 95% CI 1.02, 4.19; p=0.045; Table 5). Furthermore, increasing 
HOMA1-IR was associated with a moderate risk of progression to diabetes in adult 
Aab+ individuals who were >20 years of age (HR 1.17, 95% CI 1.05,1.31; p=0.004). We 
further evaluated changes in HOMA-IR levels from baseline to the last assessment 




change in HOMA-IR values from baseline among those who developed type 1 diabetes 
compared to those who remained diabetes free in the overall cohort (0.23 ± 1.28 vs 
0.03 ± 1.36; p<0.001). When only individuals >20 years of age were considered, the 
change in HOMA-IR for those who developed diabetes was 0.76 ± 2.39 vs a change of 
0.02 ± 0.96 in those who remained diabetes free; p<0.001). 
 
Discussion 
Here, we tested whether metabolic variables were related to progression from 
one to multiple Aabs or ultimately to type 1 diabetes as an outcome within the TrialNet 
PTP cohort. Our analysis failed to reveal a significant relationship between BMI, BMI 
percentile, weight status or insulin resistance and conversion from one to multiple islet 
Aabs. Similar findings were seen in the analysis between metabolic factors and 
progression to diabetes. The only exception was that increasing BMI% was associated 
with an increased risk of progression to type 1 diabetes in single and multiple Aab+ 
participants (Table 3). However, this effect was quite modest (HR 1.004, 95% CI 1.00, 
1.01; p=0.04). Further analysis following stratification by age revealed that obesity was 
significantly associated with increased diabetes risk among individuals 13-20 years of 
age (HR 2.03; p=0.049), whereas increasing HOMA-IR was associated with a 
moderately increased risk of diabetes in adult Aab+ individuals who were >20 years of 




The accelerator hypothesis has been advanced for a number of reasons. Recent 
data demonstrate a steady increase in the incidence of type 1 diabetes of approximately 
3-5% per year. Interestingly, recent studies have also revealed decreased 
representation of high-risk HLA alleles among participants with new-onset type 1 
diabetes, with increasing penetrance in medium, low and very low risk genotypes [6, 
37], suggesting an influence of environmental factors, such as weight status or insulin 
resistance. Indeed, rates of obesity have increased among all age groups over the past 
20-30 years [20]. However, the prevalence of obesity has begun to plateau in some 
populations [38]. By contrast, the incidence of type 1 diabetes continues to increase, 
especially among the very young [39]. 
Analysis of the effect of metabolic factors in other cohorts has also been 
inconsistent. The DPT-1 study served as the precursor to the current TrialNet study. 
Results from DPT-1 showed that both HOMA1-IR and the ratio of the first phase insulin 
response to HOMA1-IR were significantly associated with progression to diabetes 
among Aab+ individuals. In contrast to DPT-1, our findings suggest that HOMA1-IR was 
not broadly associated with diabetes risk, but rather that increasing HOMA1-IR was 
associated with a moderately increased risk among older, adult individuals. Compared 
with DPT-1, which only screened participants in the US, TrialNet is an international 
study and includes more female participants and older relatives [31]. Interestingly, at 
least for participants > 13 years of age, BMI was significantly higher in PTP participants 




The German BABYDIAB study enrolled children born to parents with diabetes 
and also failed to reveal any relationship between BMI and HOMA1-IR and the 
development of islet autoimmunity [40]. In the US Diabetes Autoimmunity Study in the 
Young (DAISY), increased height growth velocity from age 2 years was associated with 
the development of islet autoimmunity; however, there was no association with BMI or 
weight [41]. Likewise, a recent analysis of the Pittsburgh cohort found no relationship 
between obesity and insulin resistance and the number of Aabs, progression to 
diabetes, or acceleration of diabetes at a younger age [42]. Data from the US SEARCH 
study [18], the Philadelphia Pediatric Diabetes Registry [43], and national Catalan [44] 
and Australian cohorts [45] have also failed to support the accelerator hypothesis. The 
Australian BABYDIAB study did uncover an association between BMI at age 2 years 
and islet autoimmunity, but progression to diabetes in this cohort was not assessed [46]. 
Thus, the preponderance of data from multiple cohorts, including ours, does not provide 
strong support for the accelerator hypothesis. 
A number of important limitations illustrate the inherent difficulty of studying this 
question. First, participants are recruited into TrialNet and other cohorts based on 
having a blood relative with type 1 diabetes, such that genetic factors may play a 
predominant role. Indeed, high-risk HLA alleles were present in about two-thirds of our 
study population. Genome-wide association studies have identified additional risk loci 
including non-HLA genes such as INS, PTPN22, GLIS3, IL2RA, UBASH3A and HLA 




recruitment of future natural history studies may benefit from active incorporation of 
individuals with more diverse and lower risk HLA and non-HLA alleles, such that an 
influence of environmental factors may be more pronounced. 
HOMA1-IR was used in our studies and many others and serves as a surrogate 
marker of insulin resistance. Practically incorporating a gold standard measure, such as 
the hyperinsulinaemic-euglycaemic clamp, into large epidemiological studies would be 
more precise but challenging and expensive. Moreover, the average BMI of the PTP 
cohort was 22 kg/m2, and obese participants tended to be older. Thus, it would be 
useful to test our findings in a cohort enriched for younger participants with higher BMI 
values. In addition, BMI and HOMA1-IR were collected at baseline, but perhaps 
assessment of dynamic changes in metabolic variables would provide additional insight 
into how these factors influence risk [49]. To this end, we explored changes in HOMA1-
IR and the development of diabetes, and interestingly found that individuals who 
progressed to diabetes exhibited a significantly larger increase in HOMA1-IR values 
compared with those who remained diabetes free. 
Finally, our results revealed a significantly increased risk of diabetes among 
obese, peripubertal individuals aged 13-20 yrs. The incidence of type 1 diabetes 
exhibits a peak around the pubertal transition, a time associated with changes in 
secretion patterns of sex hormones that also impact insulin sensitivity. Thus, it is 
biologically plausible that obesity may compound these effects, and further increase 




staging was not collected for our study participants, data of this type would help better 
contextualise these findings [50]. 
In summary, we failed to demonstrate a pervasive effect of metabolic factors on 
diabetes risk. However, our results support a common sense approach towards 
maintenance of normal weight status in at-risk Aab+ individuals, especially during the 
pubertal transition and in older participants to avoid the development of insulin 
resistance. These data also suggest that efforts to identify other potentially modifiable 
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Table 1 PTP participant characteristics by autoantibody status 
Characteristics Group 1:single Aab+ 
(n=1,310) 
Group 2:multiple Aab+ 
(n=1,897) 
Group 1 vs group 2 
(p value) 
Age at initial screening     





  Mean (SD) 23.66 (14.45) 14.8 (11.55) <0.001 
Sex, n (%)   <0.0001b 
  Male 508 (38.78) 947 (49.92)  
  Female 797 (60.84) 939 (49.50) 
  Unknown/not reported 5 (0.38) 11 (0.58) 
Race, n (%)   0.01b 
  White 1082 (82.60) 1645 (86.72)  
  African-American 30 (2.29) 59 (3.11) 
  Asian 20 (1.53) 21 (1.11) 
  American Indian 4 (0.31) 4 (0.21) 
  Native Hawaiian, Pacific 
Islander 
3 (0.23) 2 (0.11) 
  Other 134 (10.23) 133 (7.01) 
  Unknown/not reported 37 (2.83) 33 (1.74) 
Ethnicity, n (%)   <0.001b 
  Hispanic 203 (15.50) 187 (9.86)  
  Non-Hispanic 1049 (80.08) 1622 (85.50) 
  Unknown/not reported 58 (4.43) 88 (4.64) 
Relationship to proband, n (%)    <0.001b 
  Sibling 472 (36.03) 1103 (58.14)  
  Offspring 213 (16.26) 378 (19.93) 
  Parent 482 (36.79) 245 (12.92) 
  Other 128 (9.77) 142 (7.49) 
  Unknown/not reported 15 (1.15) 29 (1.53) 
Number of positive Aabs at initial 
screen, n (%) 
   
  0 0 (0.00) 0 (0.00)  
  1 1310 (100.00) 0 (0.00) 
  2 0 (0.00) 774 (40.80) 
  3 0 (0.00) 556 (29.31) 
  4 0 (0.00) 392 (20.66) 
  5 0 (0.00) 175(9.23) 
HLA, n (%)   <0.001b 









  Unknown/not reported 191 (14.58) 318 (16.76) 
Weight category, n (%)   <0.001b 
  Underweight 69 (5.27) 131 (6.91)  
  Normal 611 (46.64) 1020 (53.77) 
  Overweighta 278 (21.22) 282 (14.87) 
  Obesea 250 (19.08) 263 (13.86) 
  Unknown 102 (7.79) 201 (10.60) 
Weight (kg) mean (SD) 61.05 (27.26) 47.65 (26.67) <0.001 
Height (cm) mean (SD) 155.9 (22.55) 145.14 (26.02) <0.001 
BMI (percentile) mean (SD) 67.75 (28.33) 63.05 (29.0) <0.001 
HOMA1-IR mean (SD) 1.99 (2.08) 1.75 (1.46) <0.001 
aObese defined as a BMI ≥30 kg/m2 and/or BMI% ≥95%; overweight defined as BMI ≥25 kg/m2 and <30 kg/m2 and/or 
BMI% ≥85% and <95%; normal weight defined as BMI ≥18.5 kg/m2 and <25 kg/m2 and/or BMI% ≥5% and <85%; 








Table 2 PTP participant characteristics by BMI category 
 




Obese vs non-obese 
(p value) 
Age at initial screening   <0.001 
  Median (Q1–Q3) 28.24 (11.07–38.87) 11.91 (7.29–23.99)  
   Mean (SD) 25.37 (14.34) 16.75 (12.81) 
Sex, n (%)   0.44 
  Male 227 (44.25) 1103 (46.13)  
  Female 285 (55.56) 1277 (53.41) 
  Unknown/not reported 1 (0.19) 11 (0.46) 
Race, n (%)   0.009 
  White 407 (79.34) 2053 (85.86)  
  African-American 22 (4.29) 60 (2.51) 
  Other 63 (12.28) 234 (9.79) 
  Unknown/not reported 21 (4.09) 44 (1.84) 
Number of positive Aabs 
at initial screen, n (%) 
  0.0004 
  1 250 (48.73) 958 (40.07)  
  2+ 263 (51.27) 1433 (59.93) 
 






Table 3 Univariate results of possible risk factors with progression outcomes 
 
Factor Time to progression 
to multiple Aab+ 
 Time to progression 
to type 1 diabetes 
HR (95% CI) p value  HR (95% CI) p value 
Age at initial screening 0.98 (0.97, 0.99) 0.001  0.95 (0.947, 0.96) <0.001 
Sex      
  Female (ref)      
  Male 1.36 (1.08, 1.71) 0.01  1.34 (1.15, 1.57) <0.001 
HLA (if DR3 or DR4) 
 
     
  Absent (ref)      
  Present 1.38 (0.99, 1.93) 0.06  1.96 (1.45, 2.65) <0.001 
Relationship to proband      
  Non-first degree (ref)      
  First degree 1.52 (0.98, 2.37) 0.06  1.02(0.77, 1.35) 0.90 
Race      
  White (ref)      
  African-American 0.68 (0.28, 1.66) 0.40  1.10(0.68, 1.78) 0.71 
  Other 0.63 (0.42, 0.92) 0.02  0.74(0.57, 0.98) 0.03 
Aab positivity      
  Single positive (ref)      
  Multiple positive    8.31(6.46, 10.69) <0.001 
BMI categories      
  Normal (ref)      
  Underweight 0.89 (0.52, 1.09) 0.66  1.90(1.46, 2.47) <0.001 
  Overweighta 0.64 (0.46, 0.88) 0.01  0.80(0.64, 1.00) 0.054 
  Obesea 0.80 (0.59, 1.09) 0.16  0.77(0.60, 0.98) 0.032 
BMI (kg/m2) 0.97 (0.95, 0.99) 0.01  0.93(0.92, 0.95) <0.001 




HOMA1-IR 1.02 (0.95, 1.09) 0.67  0.95(0.90, 1.02) 0.14 
aObese defined as a BMI ≥30 kg/m2 and/or BMI% ≥95%; overweight defined as BMI ≥25 kg/m2 and <30 kg/m2 and/or 
BMI% ≥85% and <95%; normal weight defined as BMI ≥18.5 kg/m2 and <25 kg/m2 and/or BMI% ≥5% and <85%; 





Table 4 Multivariate analysis of progression of islet autoimmunity and progression 
to type 1 diabetes 
 
Variable Time to progression 
to multiple Aabsb 
 Time to progression 
to type 1 diabetesb 
HR (95% CI)c p value  HR (95% CI)c p value 
BMI (kg/m2) 1.00 (0.97, 1.02) 0.73  1.01 (0.99, 1.03) 0.29 
BMI%  1.00 (0.99, 1.01) 0.27  1.004 (1.0002, 
1.007) 
0.04 
HOMA1-IR 0.96 (0.87, 1.07) 0.47  1.02 (0.95, 1.09) 0.56 
BMI categoriesa 	  	          
Underweight vs normal 0.89 (0.50, 1.60) 0.70  0.99 (0.73, 1.35) 0.96 
Overweight vs normal 0.84 (0.58, 1.21) 0.34  1.25 (0.98, 1.60) 0.08 
Obese vs normal 1.01 (0.70, 1.45) 0.96  1.26 (0.96, 1.65) 0.10 
Obese vs non-obese 
(overweight/normal/underwei
ght) 
1.20 (0.84, 1.69) 0.34  1.20 (0.92, 1.56) 0.18 
aObese defined as a BMI ≥30 kg/m2 and/or BMI% ≥95%; overweight defined as BMI ≥25 kg/m2 and <30 kg/m2 and/or 
BMI% ≥85% and <95%; normal weight defined as BMI ≥18.5 kg/m2 and <25 kg/m2 and/or BMI% ≥5% and <85%; 
underweight defined as BMI ≤18.5 kg/m2 and/or BMI% ≤5%. Reference group defined as normal weight 
bCox proportional hazard model adjusted by age at initial screen, sex, HLA risk, relationship to proband and race 




Table 5 Cox proportional hazard model of type 1 diabetes development with stratification by number of 
positive Aabs and age at initial screening 
Variable HR (95% CI) p valueb 
Aab statusb   
  Confirmed single Aab+ (n=1,310)   
    BMI (kg/m2) 1.01 (0.96, 1.07) 0.74 
    BMI% 1.01 (0.99, 1.02) 0.24 
    Obese vs normala 1.17 (0.54, 2.55) 0.68 
    Overweight vs normala 1.20 (0.57, 2.50) 0.63 
    Underweight vs normala 1.32 (0.40, 4.47) 0.65 
    Obese vs non-obesea 1.09 (0.53, 2.23) 0.82 
    HOMA1-IR 1.09 (0.93, 1.28) 0.30 
  Multiple Aab+ (n=1,897)   
    BMI (kg/m2) 1.01 (0.99, 1.04) 0.31 
    BMI% 1.00 (0.99, 1.01) 0.06 
    Obese vs normala 1.31 (0.97, 1.75) 0.08 
    Overweight vs normala 1.26 (0.96, 1.64) 0.09 
    Underweight vs normala 1.07 (0.78, 1.47) 0.69 
    Obese vs non-obesea 1.24 (0.93, 1.64) 0.15 
    HOMA1-IR 1.05 (0.98, 1.13) 0.15 
Age at initial screenb   
  Age <13 years (n=1632)   
    BMI% 1.01 (0.99, 1.01) 0.06 
    Obese vs normala 1.28 (0.91, 1.80) 0.16 
    Overweight vs normala 1.28 (0.95, 1.74) 0.11 
    Underweight vs normala 1.00 (0.72, 1.38) 0.998 
    Obese vs non-obesea 1.23 (0.88, 1.71) 0.23 
    HOMA1-IR 0.99 (0.90, 1.09) 0.83 
  Age 13-20 years (n=532)   
    BMI% 1.00 (0.99, 1.01) 0.65 
    Obese vs normala 2.06 (1.02, 4.19) 0.045 
    Overweight vs normala 1.37 (0.70, 2.67) 0.36 
    Underweight vs normala 1.43 (0.33, 6.09) 0.63 
    Obese vs non-obesea 1.92 (0.96, 3.84) 0.064 
    HOMA1-IR 1.11 (0.96, 1.28) 0.15 
  Age > 20 years (n=1,039)   
    BMI (kg/m2) 0.99 (0.95, 1.03) 0.57 
    BMI% 1.00 (0.99, 1.01) 0.80 
    Obese vs normala 0.83 (0.45, 1.51) 0.53 
    Overweight vs normala 0.97 (0.54, 1.77) 0.93 
    Underweight vs normala NA NA 
    Obese vs non-obesea 0.83 (0.48, 1.45) 0.52 
    HOMA1-IR 1.17 (1.05, 1.31) 0.004 
aObese defined as a BMI ≥30 kg/m2 and/or BMI% ≥95%; overweight defined as BMI ≥25 kg/m2 and <30 kg/m2 and/or 




underweight defined as BMI ≤18.5 kg/m2 and/or BMI% ≤5%. Reference group defined as normal weight, and non-
obese defined as underweight/normal/overweight 
bCox proportional hazard model adjusted by age at initial screen, sex, HLA risk, relationship to proband, race and 




[1]	   Onkamo	  P,	  Vaananen	  S,	  Karvonen	  M,	  Tuomilehto	  J	  (1999)	  Worldwide	  increase	  in	  incidence	  of	  
Type	  I	  diabetes-­‐-­‐the	  analysis	  of	  the	  data	  on	  published	  incidence	  trends.	  Diabetologia	  42:	  1395-­‐1403	  
[2]	   DIAMOND	  Project	  Group	  (2006)	  Incidence	  and	  trends	  of	  childhood	  type	  1	  diabetes	  worldwide	  
1990-­‐1999.	  Diabetic	  medicine	  23:	  857-­‐866	  
[3]	   Patterson	  CC,	  Dahlquist	  GG,	  Gyurus	  E,	  Green	  A,	  Soltesz	  G	  (2009)	  Incidence	  trends	  for	  childhood	  
type	  1	  diabetes	  in	  Europe	  during	  1989-­‐2003	  and	  predicted	  new	  cases	  2005-­‐20:	  a	  multicentre	  
prospective	  registration	  study.	  Lancet	  373:	  2027-­‐2033	  
[4]	   Lawrence	  JM,	  Imperatore	  G,	  Dabelea	  D,	  et	  al.	  (2014)	  Trends	  in	  incidence	  of	  type	  1	  diabetes	  
among	  non-­‐hispanic	  white	  youth	  in	  the	  United	  States,	  2002-­‐2009.	  Diabetes	  63:	  3938-­‐3945	  
[5]	   Donath	  MY,	  Hess	  C,	  Palmer	  E	  (2014)	  What	  is	  the	  role	  of	  autoimmunity	  in	  type	  1	  diabetes?	  A	  
clinical	  perspective.	  Diabetologia	  57:	  653-­‐655	  
[6]	   Fourlanos	  S,	  Varney	  MD,	  Tait	  BD,	  et	  al.	  (2008)	  The	  rising	  incidence	  of	  type	  1	  diabetes	  is	  
accounted	  for	  by	  cases	  with	  lower-­‐risk	  human	  leukocyte	  antigen	  genotypes.	  Diabetes	  care	  31:	  1546-­‐
1549	  
[7]	   Redondo	  MJ,	  Yu	  L,	  Hawa	  M,	  et	  al.	  (2001)	  Heterogeneity	  of	  type	  I	  diabetes:	  analysis	  of	  
monozygotic	  twins	  in	  Great	  Britain	  and	  the	  United	  States.	  Diabetologia	  44:	  354-­‐362	  
[8]	   Bodansky	  HJ,	  Staines	  A,	  Stephenson	  C,	  Haigh	  D,	  Cartwright	  R	  (1992)	  Evidence	  for	  an	  
environmental	  effect	  in	  the	  aetiology	  of	  insulin	  dependent	  diabetes	  in	  a	  transmigratory	  population.	  BMJ	  
(Clinical	  research	  ed)	  304:	  1020-­‐1022	  
[9]	   Bach	  JF	  (2002)	  The	  effect	  of	  infections	  on	  susceptibility	  to	  autoimmune	  and	  allergic	  diseases.	  
The	  New	  England	  journal	  of	  medicine	  347:	  911-­‐920	  
[10]	   Schneider	  DA,	  von	  Herrath	  MG	  (2014)	  Potential	  viral	  pathogenic	  mechanism	  in	  human	  type	  1	  
diabetes.	  Diabetologia	  57:	  2009-­‐2018	  
[11]	   Vaarala	  O,	  Atkinson	  MA,	  Neu	  J	  (2008)	  The	  "perfect	  storm"	  for	  type	  1	  diabetes:	  the	  complex	  
interplay	  between	  intestinal	  microbiota,	  gut	  permeability,	  and	  mucosal	  immunity.	  Diabetes	  57:	  2555-­‐
2562	  
[12]	   Hypponen	  E,	  Laara	  E,	  Reunanen	  A,	  Jarvelin	  MR,	  Virtanen	  SM	  (2001)	  Intake	  of	  vitamin	  D	  and	  risk	  
of	  type	  1	  diabetes:	  a	  birth-­‐cohort	  study.	  Lancet	  358:	  1500-­‐1503	  
[13]	   Kimpimaki	  T,	  Kupila	  A,	  Hamalainen	  AM,	  et	  al.	  (2001)	  The	  first	  signs	  of	  beta-­‐cell	  autoimmunity	  
appear	  in	  infancy	  in	  genetically	  susceptible	  children	  from	  the	  general	  population:	  the	  Finnish	  Type	  1	  
Diabetes	  Prediction	  and	  Prevention	  Study.	  The	  Journal	  of	  clinical	  endocrinology	  and	  metabolism	  86:	  
4782-­‐4788	  
[14]	   Howard	  SG,	  Lee	  DH	  (2012)	  What	  is	  the	  role	  of	  human	  contamination	  by	  environmental	  
chemicals	  in	  the	  development	  of	  type	  1	  diabetes?	  Journal	  of	  epidemiology	  and	  community	  health	  66:	  
479-­‐481	  
[15]	   Wilkin	  TJ	  (2008)	  Diabetes:	  1	  and	  2,	  or	  one	  and	  the	  same?	  Progress	  with	  the	  accelerator	  




[16]	   Johansson	  C,	  Samuelsson	  U,	  Ludvigsson	  J	  (1994)	  A	  high	  weight	  gain	  early	  in	  life	  is	  associated	  with	  
an	  increased	  risk	  of	  type	  1	  (insulin-­‐dependent)	  diabetes	  mellitus.	  Diabetologia	  37:	  91-­‐94	  
[17]	   Knerr	  I,	  Wolf	  J,	  Reinehr	  T,	  et	  al.	  (2005)	  The	  'accelerator	  hypothesis':	  relationship	  between	  
weight,	  height,	  body	  mass	  index	  and	  age	  at	  diagnosis	  in	  a	  large	  cohort	  of	  9,248	  German	  and	  Austrian	  
children	  with	  type	  1	  diabetes	  mellitus.	  Diabetologia	  48:	  2501-­‐2504	  
[18]	   Dabelea	  D,	  D'Agostino	  RB,	  Jr.,	  Mayer-­‐Davis	  EJ,	  et	  al.	  (2006)	  Testing	  the	  accelerator	  hypothesis:	  
body	  size,	  beta-­‐cell	  function,	  and	  age	  at	  onset	  of	  type	  1	  (autoimmune)	  diabetes.	  Diabetes	  care	  29:	  290-­‐
294	  
[19]	   Kibirige	  M,	  Metcalf	  B,	  Renuka	  R,	  Wilkin	  TJ	  (2003)	  Testing	  the	  accelerator	  hypothesis:	  the	  
relationship	  between	  body	  mass	  and	  age	  at	  diagnosis	  of	  type	  1	  diabetes.	  Diabetes	  care	  26:	  2865-­‐2870	  
[20]	   Fryar	  CD	  CM,	  Ogden	  CL	  (2012)	  Prevalence	  of	  Obesity	  Among	  Children	  and	  Adolescents:	  United	  
States,	  Trends	  1963–1965	  Through	  2009–2010.	  Available	  from	  
http://www.cdc.gov/nchs/data/hestat/obesity_child_09_10/obesity_child_09_10.pdf.	  accessed	  29	  
March	  2014.	  
[21]	   Xu	  P,	  Cuthbertson	  D,	  Greenbaum	  C,	  Palmer	  JP,	  Krischer	  JP	  (2007)	  Role	  of	  insulin	  resistance	  in	  
predicting	  progression	  to	  type	  1	  diabetes.	  Diabetes	  care	  30:	  2314-­‐2320	  
[22]	   Chase	  HP,	  Cuthbertson	  DD,	  Dolan	  LM,	  et	  al.	  (2001)	  First-­‐phase	  insulin	  release	  during	  the	  
intravenous	  glucose	  tolerance	  test	  as	  a	  risk	  factor	  for	  type	  1	  diabetes.	  The	  Journal	  of	  pediatrics	  138:	  244-­‐
249	  
[23]	   Sosenko	  JM,	  Skyler	  JS,	  Mahon	  J,	  et	  al.	  (2011)	  Validation	  of	  the	  Diabetes	  Prevention	  Trial-­‐type	  1	  
risk	  score	  in	  the	  TrialNet	  Natural	  History	  Study.	  Diabetes	  care	  34:	  1785-­‐1787	  
[24]	   Sosenko	  JM,	  Skyler	  JS,	  Mahon	  J,	  et	  al.	  (2014)	  Use	  of	  the	  Diabetes	  Prevention	  Trial-­‐type	  1	  risk	  
score	  (DPTRS)	  for	  improving	  the	  accuracy	  of	  the	  risk	  classification	  of	  type	  1	  diabetes.	  Diabetes	  care	  37:	  
979-­‐984	  
[25]	   Sosenko	  JM,	  Skyler	  JS,	  Mahon	  J,	  et	  al.	  (2012)	  The	  application	  of	  the	  Diabetes	  Prevention	  Trial-­‐
type	  1	  risk	  score	  for	  identifying	  a	  preclinical	  state	  of	  type	  1	  diabetes.	  Diabetes	  care	  35:	  1552-­‐1555	  
[26]	   Skyler	  JS,	  Greenbaum	  CJ,	  Lachin	  JM,	  et	  al.	  (2008)	  Type	  1	  Diabetes	  TrialNet-­‐-­‐an	  international	  
collaborative	  clinical	  trials	  network.	  Annals	  of	  the	  New	  York	  Academy	  of	  Sciences	  1150:	  14-­‐24	  
[27]	   Mahon	  JL,	  Sosenko	  JM,	  Rafkin-­‐Mervis	  L,	  et	  al.	  (2009)	  The	  TrialNet	  Natural	  History	  Study	  of	  the	  
Development	  of	  Type	  1	  Diabetes:	  objectives,	  design,	  and	  initial	  results.	  Pediatric	  diabetes	  10:	  97-­‐104	  
[28]	   Yu	  L,	  Boulware	  DC,	  Beam	  CA,	  et	  al.	  (2012)	  Zinc	  transporter-­‐8	  autoantibodies	  improve	  prediction	  
of	  type	  1	  diabetes	  in	  relatives	  positive	  for	  the	  standard	  biochemical	  autoantibodies.	  Diabetes	  care	  35:	  
1213-­‐1218	  
[29]	   Greenbaum	  CJ,	  Mandrup-­‐Poulsen	  T,	  McGee	  PF,	  et	  al.	  (2008)	  Mixed-­‐meal	  tolerance	  test	  versus	  
glucagon	  stimulation	  test	  for	  the	  assessment	  of	  beta-­‐cell	  function	  in	  therapeutic	  trials	  in	  type	  1	  diabetes.	  
Diabetes	  care	  31:	  1966-­‐1971	  
[30]	   Vehik	  K,	  Beam	  CA,	  Mahon	  JL,	  et	  al.	  (2011)	  Development	  of	  autoantibodies	  in	  the	  TrialNet	  
Natural	  History	  Study.	  Diabetes	  care	  34:	  1897-­‐1901	  
[31]	   Sosenko	  JM,	  Mahon	  J,	  Rafkin	  L,	  et	  al.	  (2011)	  A	  comparison	  of	  the	  baseline	  metabolic	  profiles	  
between	  Diabetes	  Prevention	  Trial-­‐Type	  1	  and	  TrialNet	  Natural	  History	  Study	  participants.	  Pediatric	  
diabetes	  12:	  85-­‐90	  
[32]	   	  (2002)	  Effects	  of	  insulin	  in	  relatives	  of	  patients	  with	  type	  1	  diabetes	  mellitus.	  The	  New	  England	  




[33]	   Ogden	  CL,	  Kuczmarski	  RJ,	  Flegal	  KM,	  et	  al.	  (2002)	  Centers	  for	  Disease	  Control	  and	  Prevention	  
2000	  growth	  charts	  for	  the	  United	  States:	  improvements	  to	  the	  1977	  National	  Center	  for	  Health	  
Statistics	  version.	  Pediatrics	  109:	  45-­‐60	  
[34]	   American	  Diabetes	  Association	  (2014)	  Standards	  of	  medical	  care	  in	  diabetes-­‐-­‐2014.	  Diabetes	  
care	  37(Suppl	  1):	  S14-­‐S80	  
[35]	   Lin	  DY,	  L.	  J.	  Wei,	  and	  Z.	  Ying.	  (1993)	  Checking	  the	  Cox	  model	  with	  cumulative	  sums	  of	  
Martingale-­‐based	  residuals.	  Biometrika	  80:	  557–572	  
[36]	   Erlich	  H,	  Valdes	  AM,	  Noble	  J,	  et	  al.	  (2008)	  HLA	  DR-­‐DQ	  haplotypes	  and	  genotypes	  and	  type	  1	  
diabetes	  risk:	  analysis	  of	  the	  type	  1	  diabetes	  genetics	  consortium	  families.	  Diabetes	  57:	  1084-­‐1092	  
[37]	   Steck	  AK,	  Armstrong	  TK,	  Babu	  SR,	  Eisenbarth	  GS	  (2011)	  Stepwise	  or	  linear	  decrease	  in	  
penetrance	  of	  type	  1	  diabetes	  with	  lower-­‐risk	  HLA	  genotypes	  over	  the	  past	  40	  years.	  Diabetes	  60:	  1045-­‐
1049	  
[38]	   Ogden	  CL,	  Carroll	  MD,	  Kit	  BK,	  Flegal	  KM	  (2014)	  Prevalence	  of	  childhood	  and	  adult	  obesity	  in	  the	  
United	  States,	  2011-­‐2012.	  JAMA	  311:	  806-­‐814	  
[39]	   	  (2000)	  Variation	  and	  trends	  in	  incidence	  of	  childhood	  diabetes	  in	  Europe.	  EURODIAB	  ACE	  Study	  
Group.	  Lancet	  355:	  873-­‐876	  
[40]	   Winkler	  C,	  Marienfeld	  S,	  Zwilling	  M,	  Bonifacio	  E,	  Ziegler	  AG	  (2009)	  Is	  islet	  autoimmunity	  related	  
to	  insulin	  sensitivity	  or	  body	  weight	  in	  children	  of	  parents	  with	  type	  1	  diabetes?	  Diabetologia	  52:	  2072-­‐
2078	  
[41]	   Lamb	  MM,	  Yin	  X,	  Zerbe	  GO,	  et	  al.	  (2009)	  Height	  growth	  velocity,	  islet	  autoimmunity	  and	  type	  1	  
diabetes	  development:	  the	  Diabetes	  Autoimmunity	  Study	  in	  the	  Young.	  Diabetologia	  52:	  2064-­‐2071	  
[42]	   Cedillo	  M,	  Libman	  IM,	  Arena	  VC,	  et	  al.	  (2015)	  Obesity,	  islet	  cell	  autoimmunity,	  and	  
cardiovascular	  risk	  factors	  in	  youth	  at	  onset	  of	  type	  1	  autoimmune	  diabetes.	  The	  Journal	  of	  clinical	  
endocrinology	  and	  metabolism	  100:	  E82-­‐86	  
[43]	   Lipman	  TH,	  Levitt	  Katz	  LE,	  Ratcliffe	  SJ,	  et	  al.	  (2013)	  Increasing	  incidence	  of	  type	  1	  diabetes	  in	  
youth:	  twenty	  years	  of	  the	  Philadelphia	  Pediatric	  Diabetes	  Registry.	  Diabetes	  care	  36:	  1597-­‐1603	  
[44]	   Gimenez	  M,	  Aguilera	  E,	  Castell	  C,	  de	  Lara	  N,	  Nicolau	  J,	  Conget	  I	  (2007)	  Relationship	  between	  BMI	  
and	  age	  at	  diagnosis	  of	  type	  1	  diabetes	  in	  a	  Mediterranean	  area	  in	  the	  period	  of	  1990-­‐2004.	  Diabetes	  
care	  30:	  1593-­‐1595	  
[45]	   O'Connell	  MA,	  Donath	  S,	  Cameron	  FJ	  (2007)	  Major	  increase	  in	  type	  1	  diabetes:	  no	  support	  for	  
the	  accelerator	  hypothesis.	  Diabetic	  medicine	  24:	  920-­‐923	  
[46]	   Couper	  JJ,	  Beresford	  S,	  Hirte	  C,	  et	  al.	  (2009)	  Weight	  gain	  in	  early	  life	  predicts	  risk	  of	  islet	  
autoimmunity	  in	  children	  with	  a	  first-­‐degree	  relative	  with	  type	  1	  diabetes.	  Diabetes	  care	  32:	  94-­‐99	  
[47]	   Barrett	  JC,	  Clayton	  DG,	  Concannon	  P,	  et	  al.	  (2009)	  Genome-­‐wide	  association	  study	  and	  meta-­‐
analysis	  find	  that	  over	  40	  loci	  affect	  risk	  of	  type	  1	  diabetes.	  Nature	  genetics	  41:	  703-­‐707	  
[48]	   Steck	  AK,	  Dong	  F,	  Wong	  R,	  et	  al.	  (2014)	  Improving	  prediction	  of	  type	  1	  diabetes	  by	  testing	  non-­‐
HLA	  genetic	  variants	  in	  addition	  to	  HLA	  markers.	  Pediatric	  diabetes	  15:	  355-­‐362	  
[49]	   Barker	  JM,	  Goehrig	  SH,	  Barriga	  K,	  et	  al.	  (2004)	  Clinical	  characteristics	  of	  children	  diagnosed	  with	  
type	  1	  diabetes	  through	  intensive	  screening	  and	  follow-­‐up.	  Diabetes	  care	  27:	  1399-­‐1404	  
[50]	   Ziegler	  AG,	  Meier-­‐Stiegen	  F,	  Winkler	  C,	  Bonifacio	  E	  (2012)	  Prospective	  evaluation	  of	  risk	  factors	  
for	  the	  development	  of	  islet	  autoimmunity	  and	  type	  1	  diabetes	  during	  puberty-­‐-­‐TEENDIAB:	  study	  design.	  
Pediatric	  diabetes	  13:	  419-­‐424	  
	  
Supplemental Table 1: Univariate Results of Possible Risk Factors with Progression Outcomes 
 
Factor Time to progression  
to multiple Aab + 
Time to progression  
to type 1 diabetes 
HR (95% CI) p-value HR (95% CI) p-value 




     Female (ref) 













HLA (If DR3 or DR4) 
      Absent (ref) 
      Present 
 
 











Relationship to proband 
      Non-first Degree 
(ref) 














     White (ref)  
     African American 


















     Single positive (ref) 












BMI categories#     
Normal/Underweight(ref) 
      Overweight# 

















BMI (kg/m2) 0.97(0.95-0.99) 0.01 0.93(0.92-0.95) <0.001 
BMI% 0.994(0.99-
0.998) 
0.01 1.00(0.99-1.01) 0.14 
HOMA1-IR 1.02(0.95-1.09) 0.67 0.95(0.90-1.02) 0.14 
# Obese defined as a BMI ≥ 30 and/or BMI% ≥ 95%, Overweight defined as BMI > 25 and < 30  
and/or BMI% > 85% and < 95%. Reference group defined as normal or underweight. 















Supplemental Figure 1:  Final Analyses Cohort.  Non-diabetic first, second, or third-degree relatives of individuals with 
type 1 diabetes were screened for the presence of pancreatic islet Aabs in a step-wise fashion.  Confirmed Aab positive 
(Aab+) individuals were invited to participate in longitudinal observation with either semi-annual or annual monitoring. A 
total of 134,937 eligible individuals were screened from 2001 through June 30, 2014.  A total of 2,299 individuals were 
confirmed on repeat testing to be single Aab (GAD65, insulin, or IA-2/ICA512) positive, while a total of 2,960 individuals 
were identified to be multiple Aab+ (GAD65, insulin, IA-2/ICA512, ICA, or ZnT8).  Analyses presented here focus on those 
who had at least one monitoring visit (1,310 single Aab+ and 1,897 multiple Aab+ subjects).  Within the single Aab+ 
group, 288 subjects progressed to multiple Aab+ status, while 68 individuals progressed to diabetes.  Within the multiple 
Aab+ group, 579 individuals progressed to T1D.  PTP = Pathway to Prevention; T1D = Type 1 Diabetes; Aab+ = 
autoantibody-positive; Aab- = autoantibody-negative. *Indicates confirmed positivity of the same type of islet autoantigen. 
 
Supplemental Figure 2:   
 
Supplemental Figure 2:  Time to Type 1 Diabetes by BMI Group in Subjects 13-20 years of age.  Kaplan-Meier plots of 
diabetes-free survival in 532 PTP Participants 13-20 years of age stratified by BMI category.  BMI category divisions included 
underweight (BMI <18.5 and/or BMI% <5%) combined with normal weight subjects (BMI ≥ 18.5 kg/m2 and < 25 kg/m2 and/or BMI 
percentile ≥ 5% and < 85%); overweight (BMI ≥ 25 kg/m2 and < 30 kg/m2 and/or BMI percentile ≥ 85% and < 95%); and obese (BMI ≥ 
30 kg/m2 and/or BMI percentile ≥95%).  The HR of obese subjects is 2.03 (95% CI 1.00-4.10); p=0.049 vs. normal/underweight, 
adjusted for age at initial screen, gender, HLA risk, relationship to proband, race, and number of Aabs at initial screen.  The HR of 
overweight vs. normal/underweight is 1.35 (95% CI 0,69-2.64); p=0.38, whereas the HR of obese vs. non-obese is 1.92 (95% CI 
0.96-3.84); p=0.064.   
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